Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > funny when someone rises concerns re eg funding which
View:
Post by edrose on Jun 11, 2020 9:33am

funny when someone rises concerns re eg funding which

is far from beeing done they call us bashers  these pumpers don't want to see that r107 will take yers before we get results   they only have few results in animals  

kly as excellent phase2 in humans and our phase3  only takes one year  

WITHOUT FUNDING WITH BARDA WHICH IS NOT GUARANTEED  WE ARE GIVING AWAY 49% OF KLY TO SALZMAN FOR R107   OUR PRODUCT IS MUCH CLOSER TO GET APPROVED   

IF THE 5 MILLION PP IS SUCCESSFULL WE SHOULD NOT BUY SALZMAN

STRANGE THEY ARE NOT GIVING US UPDAE ON PP   AGAIN THIS BOARD AND CEO KEEP RETAIL INVESTORS IN THE DARK
Comment by Jack4000 on Jun 11, 2020 9:41am
This post has been removed in accordance with Community Policy
Comment by JMark80 on Jun 11, 2020 11:54am
$10mm, not $20mm. Golly!!!!
Comment by Looking4Doubles on Jun 11, 2020 12:06pm
So you are saying the nitric oxide treatment has no chance of being used for lung illnesses, COVID, or Cili ? ?  Or . . maybe that sales won't happen after the cili reserach? ? Everyone is entitled to their own opinion - If you don't see an opportunity, this may not be for you, or ED.   I have answered his questions before and he just asks the same question again without ...more  
Comment by JMark80 on Jun 11, 2020 12:18pm
No, I was saying phase 3 for GvHD was estimated by company at $10mm, not $20mm. However, I don't think R-107 will be developed for COVID. My previous post raised question about sales after CILI.
Comment by Jack4000 on Jun 11, 2020 2:16pm
This post has been removed in accordance with Community Policy
Comment by JMark80 on Jun 11, 2020 2:32pm
Why do you think it would take $6mm to get to phase 3, then another $10mm to finish phase 3. Could it be the $10mm included $6mm plus milestone payments and contingencies? I said Golly to mock you, because it makes you sound like a 90 year old.
Comment by Jack4000 on Jun 11, 2020 2:35pm
This post has been removed in accordance with Community Policy
Comment by JMark80 on Jun 11, 2020 2:40pm
No it isn't, bruh.
Comment by Jack4000 on Jun 11, 2020 2:59pm
This post has been removed in accordance with Community Policy
Comment by Easyflips on Jun 11, 2020 3:35pm
This post has been removed in accordance with Community Policy
Comment by JMark80 on Jun 11, 2020 6:22pm
You're an idiot. 
Comment by Looking4Doubles on Jun 11, 2020 10:05am
Hey ED !   Why don't you finally level with posters.  You are obviously bashing this stock for personal reasons - How many shares have you shorted and why do you think they will NOT get government contracts AND sales for Cili, when they have already gotten 84 million?  Keep in mind that Salzman is a "strategic" partner on Cili and have been working with top ...more  
Comment by JMark80 on Jun 11, 2020 12:14pm
They haven't already "gotten" $84mm. "BARDA awarded Salzman Group a USD $84.9M contract to develop R-107 as a treatment for CILI"   "$15M has been funded and spent – $70M in follow-on funding will be released on completion of milestones" "From the $70M of revenues, Kalytera will recognize $4.2M of net operating profit". "Because ...more  
Comment by Looking4Doubles on Jun 11, 2020 1:01pm
1.) I am aware of that, but the initial definition for $84 mil says plenty. (They could have given out a $15 mil contract - they didn't.)   I worked in supply management, you don't outline a contract that big wthout "intent" 2.) As I have pointed out before, COVID could be a game changer in the U.S.  Trump DESPERATELY needs solutions to the deaths occuring BEFORE ...more  
Comment by JMark80 on Jun 11, 2020 2:29pm
So? The majority of that $85 doesn't even go to Salzman/Kalytera. Regardless, the pay off is $4.2mm, even if that's after tax, it's miniscule. This has nothing to do with Trump. 130 vaccines in development. Hundreds of treatments in development. There will be a vaccine produced before this makes it to phase 2.
Comment by JMark80 on Jun 11, 2020 11:53am
Don't bother, Ed. You bring up legitimate concerns and don't deserve to be treated like Penny. These so-called bulls are either idiots, or being manipulative until they sell.